Abstract:Abstract Background: Breast tumor initiating cells (BT-ICs) display a variety of drug-resisting mechanisms including overxpression of ATP binding cassette (ABC) transporters and anti-apoptotic molecules. Unfortunately, application of P-glycoprotein inhibitors has not been successful in several clinical trials .Based on the tumor initiating cell concept, an alternative model posits that the T-ICs are naturally resistant to chemotherapy through their quiescence and their capacity for DNA repair. Gaining a better insight into the mechanisms of BT-IC resistance to chemotherapy might therefore lead to new therapeutic targets and better anticancer strategies.Material and Methods: We generated large numbers of BT-IC-enriched cells (SK-3rd) by in vivo passage of breast cancer cells SKBR3 in NOD/SCID mice treated with epirubicin, then enriched BT-ICs again by isolating spherical clusters of self-replicating cells (“mammospheres”) from suspension cultures. Under chemotherapy pressure, compared the apoptosis between BT-IC and non BT-IC by MTT, Annexin V, DNA ladder and hochest 33342 staining, and analyzed the cell cycles by Flow cytometry. We tested the DNA repair capacity after chemo-induced DNA damage between BT-IC and non BT-IC by single cell gel electrophoresis and tested the expression of DNA damage checkpoint protein by immunoblot.Results:SK-3rd formed 40-fold more mammospheres than SKBR3 (16.7%±2.6% vs 0.5%±0.2%; P<0.001). Compared with non BT-IC, BT-IC treated with epirubicin showed more viability as assessed by MTT assay. After treated with 0.3ug/ml Epirubicin for 24 hours, withdrew the drug, and then repaired for 12, 24 hours respectively, analyzed the Annexin V positive cells in BT-IC were less than n non BT-IC(17.27%±2.3% vs 56%±6.7%; P=0.026), hochest staining also showed the similar results.SK-3rd mammospheric cells treated with or without Epirubicin arrested in G0/1 stage. Breast T-IC can repair chemo-induced DNA damage more efficiently than non BT-IC. Treated with or without Epirubicin, Sk-3rd mammospheric cells can pre-activated phosphorylated DNA chk2checkpoint (Thr68),but not in non BT-IC.Dicussion: The discovery of cancer initiating cells in solid tumors has changed our view of carcinogenesis and chemotherapy. In our study, we found that, BT-IC was more resistant than non BT-IC under the same chemotherapy pressure Although initiating cells can self-renew, they are generally quiescent, spending most of their time in G0. BT-IC treated with or without Epirubicin activated DNA checkpoint phosphorylated chk2 and arrested in G0/1 stage, which implied that BT-IC can target itself to arrest in G0/1 stage and pre-active chk2. When treated with DNA damage, BT-IC has enough time and quickly responses to repair damaged DNA, and at last contributes to the failure of chemotherapy. The new insight into the mechanisms of initiating -cell chemoresistance might allow the development of new strategies to improve targeted therapies in breast cancer. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1121.

Interference of Chk2 Reverses Chemo-Resistance of Breast Cancer Initiating Cells

Cd44(Hi)Cd24(Lo) Mammosphere-Forming Cells From Primary Breast Cancer Display Resistance To Multiple Chemotherapeutic Drugs

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Breast Cancer Initiating Cells Promote Chemoresistance by Pre-Activation of the Dna Damage Repair

Potentiated DNA Damage Response in Circulating Breast Tumor Cells Confers Resistance to Chemotherapy

Increased activity of CHK enhances the radioresistance of MCF-7 breast cancer stem cells.

Checkpoint Kinase‑1 Inhibition and Etoposide Exhibit a Strong Synergistic Anticancer Effect on Chronic Myeloid Leukemia Cell Line K562 by Impairing Homologous Recombination DNA Damage Repair

Interdependence of Homologous Recombination Repair and Cell Cycle Arrest in Response to DNA Double Strand Breaks Induced by Camptothecins

Molecular, biological characterization and drug sensitivity of chidamide-resistant MCF7 cells

Chk 1 Knockdown Confers Radiosensitization in Prostate Cancer Stem Cells

Dual Induction of Apoptosis and Senescence in Cancer Cells by Chk2 Activation: Checkpoint Activation As a Strategy Against Cancer.

The Radioresistance to Killing of A1–5 Cells Derives from Activation of the Chk1 Pathway

The Research Progress of the Mechanism of CHK2 in Tumor

Effects of ionizing radiation on ROS,apoptosis and cell cycle in breast cancer stem cells

The Role of CHK1 Varies with the Status of Oestrogen-receptor and Progesterone-receptor in the Targeted Therapy for Breast Cancer.

DNAJC12 Causes Breast Cancer Chemotherapy Resistance by Repressing DoxorubicinInduced Ferroptosis and Apoptosis Via Activation of AKT

Guarding against digestive-system cancers: Unveiling the role of Chk2 as a potential therapeutic target

The Mir-34A-5p-c-myc-chk1/chk2 Axis Counteracts Cancer Stem Cell-Like Properties and Enhances Radiosensitivity in Hepatocellular Cancer Through Repression of the DNA Damage Response

DNA Methyltransferase Inhibitor CDA-2 Synergizes with High-Dose Thiotepa and Paclitaxel in Killing Breast Cancer Stem Cells

Profiling Global Kinome Signatures of the Radioresistant MCF-7/C6 Breast Cancer Cells Using MRM-based Targeted Proteomics

Multi-Drug-Resistant Cells Enriched From Chronic Myeloid Leukemia Cells By Doxorubicin Possess Tumor-Initiating-Cell Properties